Burrard Pharmaceuticals offers complete technology transfer and know-how packages for 70+ pharmaceutical products. Each package includes master formulas, manufacturing protocols, stability data, CTD/eCTD templates, and expert consultation — delivered within 2–21 business days via our secure portal.
Injectable chemotherapy and targeted cancer therapies — sterile formulations, cytotoxic handling, and lyophilization know-how
Nanoparticle albumin-bound formulation for breast, ovarian, and non-small cell lung cancers. Complex manufacturing involving high-pressure homogenization.
View Technology Transfer → OncologyAnthracycline chemotherapy for breast cancer, leukemia, and lymphoma. Cytotoxic handling and containment manufacturing expertise required.
View Technology Transfer → OncologyNucleoside analog for pancreatic, lung, and breast cancers. Lyophilized formulation with stability-critical manufacturing process.
View Technology Transfer → OncologyPlatinum-based chemotherapy for metastatic colorectal cancer. Requires strict light-protection and temperature-controlled manufacturing.
View Technology Transfer → OncologySecond-generation platinum compound for ovarian and lung cancers. Sterile aqueous solution manufacturing with critical pH stability parameters.
View Technology Transfer →GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors — injectable and oral formulations for Type 2 diabetes
GLP-1 receptor agonist for Type 2 diabetes and weight management. Subcutaneous and long-acting injectable formulation with peptide stability expertise.
View Technology Transfer → DiabetesDPP-4 inhibitor for Type 2 diabetes. Oral tablet formulation with crystalline salt form and moisture-sensitive manufacturing.
View Technology Transfer → DiabetesDual GIP/GLP-1 receptor agonist for Type 2 diabetes. Novel peptide injectable requiring advanced formulation and device integration know-how.
View Technology Transfer → DiabetesSGLT2 inhibitor for Type 2 diabetes with cardiovascular benefits. Oral film-coated tablet with humidity-controlled manufacturing.
View Technology Transfer → DiabetesOnce-weekly GLP-1 receptor agonist for Type 2 diabetes. Pre-filled pen device formulation with Fc-fusion protein stability considerations.
View Technology Transfer →Antihypertensives, anticoagulants, statins, ACE inhibitors, beta-blockers — oral and injectable formulations
Direct Factor Xa inhibitor anticoagulant. Film-coated tablet with bioavailability-enhancing micronization and amorphous solid formulation.
View Technology Transfer → CardiovascularHMG-CoA reductase inhibitor for cholesterol management. Calcium salt tablet formulation with moisture and light sensitivity considerations.
View Technology Transfer → CardiovascularP2Y12 antiplatelet agent for heart attack and stroke prevention. Bisulfate salt with polymorphic form control in manufacturing.
View Technology Transfer → CardiovascularAngiotensin II receptor blocker for hypertension. Potassium salt tablet with tetrazole ring stability considerations.
View Technology Transfer → CardiovascularCalcium channel blocker for hypertension and angina. Besylate salt tablet with photostability and racemic formulation considerations.
View Technology Transfer →Inhaled corticosteroids, bronchodilators, antihistamines, and biologics for asthma, COPD, and allergic rhinitis
Inhaled corticosteroid prodrug for asthma. Metered-dose inhaler (MDI) and nasal spray formulations with HFA propellant technology.
View Technology Transfer → RespiratoryAnti-IgE monoclonal antibody for severe allergic asthma. Biologics manufacturing with lyophilized powder for reconstitution.
View Technology Transfer → RespiratoryInhaled corticosteroid for asthma and COPD. Nebulizer suspension and dry powder inhaler formulation know-how.
View Technology Transfer → RespiratoryLong-acting anticholinergic bronchodilator for COPD. Dry powder capsule inhalation and soft mist inhaler device formulation.
View Technology Transfer → RespiratoryLeukotriene receptor antagonist for asthma and allergic rhinitis. Sodium salt tablet with photodegradation protection requirements.
View Technology Transfer →Monoclonal antibodies and biologics for psoriasis, atopic dermatitis, rheumatoid arthritis, and other autoimmune conditions
Anti-TNF monoclonal antibody for rheumatoid arthritis, Crohn's disease, and psoriasis. Biosimilar manufacturing with CHO cell line expression systems.
View Technology Transfer → ImmunologyIL-4/IL-13 blocking antibody for atopic dermatitis and asthma. Pre-filled syringe biologics manufacturing with cold chain management.
View Technology Transfer → ImmunologyIL-17A inhibitor for moderate-to-severe plaque psoriasis. Humanized monoclonal antibody with autoinjector device formulation.
View Technology Transfer →Novel combination antibiotics for resistant bacterial infections
Anti-VEGF biologics, glaucoma treatments, dry eye therapies, and ophthalmic anti-inflammatories — sterile injectable and topical formulations
Recombinant VEGF fusion protein for wet AMD, DME, and retinal vein occlusion. Intravitreal injection requiring aseptic biologics manufacturing.
View Technology Transfer → OphthalmicFirst bispecific antibody targeting both VEGF-A and Ang-2 for AMD and DME. Novel dual-target biologics manufacturing with extended durability.
View Technology Transfer → OphthalmicAnti-VEGF monoclonal antibody Fab fragment for retinal vascular diseases. E. coli expression system with Fab refolding technology.
View Technology Transfer → OphthalmicTopical calcineurin inhibitor for dry eye disease. Complex emulsion or nanomicellar formulation for increased tear production.
View Technology Transfer → OphthalmicProstamide analog for glaucoma and ocular hypertension. Precision low-concentration ophthalmic formulation with IOP-lowering efficacy.
View Technology Transfer →Contact our team to discuss your product requirements. We respond within 24 hours.
Quality & Compliance
GMP compliant · Health Canada, FDA, EMA, TGA, PMDA submissions · Vancouver, BC